Organization Profile

You just read:

ProNAi Initiates Phase II Trial of PNT2258 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

News provided by

ProNAi Therapeutics Inc.

Jan 07, 2015, 10:00 ET